Patents by Inventor Nathalie HEUZE VOURC'H

Nathalie HEUZE VOURC'H has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF INHALED ANTIBODIES AND IMMUNOMODULATORY AGENTS FOR THE TREATMENT OR PREVENTION OF RESPIRATORY INFECTIONS
    Publication number: 20230372416
    Abstract: A combination of agents capable of binding an infectious agent, such as an antibody, an antibody derivative, or an antibody mimetic, and immunomodulatory agents, such as probiotic strains, for the treatment or prevention of respiratory infections, in particular bacterial respiratory infections. The agents capable of binding an infectious agent are administered by inhalation.
    Type: Application
    Filed: October 8, 2021
    Publication date: November 23, 2023
    Applicants: UNIVERSITÉ DE TOURS, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Nathalie HEUZE-VOURC'H, Thomas SECHER, Muriel THOMAS
  • PULMONARY DELIVERY OF ANTIBODIES
    Publication number: 20230047809
    Abstract: The present invention relates to the pulmonary delivery of antibodies or antibody derivatives.
    Type: Application
    Filed: February 1, 2021
    Publication date: February 16, 2023
    Inventors: Sylvain HUILLE, Heloise AUDAT, Alexie MAYOR, Nathalie HEUZÉ-VOURC'H, Renaud RESPAUD
  • METHODS FOR PREDICTING THE SURVIVAL TIME AND TREATMENT RESPONSIVENESS OF A PATIENT SUFFERING FROM A SOLID CANCER
    Publication number: 20180216193
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tissue sample obtained from the patient the gene expression level of FcRn ii) comparing expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when expression level determined at step i) is higher than their predetermined reference value, or providing a bad prognosis when expression levels determined at step i) are lower than their predetermined reference values.
    Type: Application
    Filed: July 21, 2016
    Publication date: August 2, 2018
    Inventors: Nathalie HEUZE VOURC'H, Emilie DALLONEAU, Konstantinos MAVRIDIS, Valérie GOUILLEUX-GRUART